227 related articles for article (PubMed ID: 31319089)
41. Autoimmune blistering dermatoses as systemic diseases.
Vassileva S; Drenovska K; Manuelyan K
Clin Dermatol; 2014; 32(3):364-75. PubMed ID: 24767184
[TBL] [Abstract][Full Text] [Related]
42. A multicentre prospective analysis of the incidence of pemphigoid diseases in Turkey.
Durdu M; Bozca BC; Enli S; Yazıcı Özgen Z; Yaylı S; Aktan Ş; Mutlu D; Erturan I; Ayvaz Çelik HH; Melikoğlu M; Pala E; Gürsel Ürün Y; Harman M; Şavk E; Işık S; Duygulu Ş; İmren IG; Fettahlıoğlu Karaman B; Kaya Erdoğan H; Kılıç A; Özçelik S; Inan K; Yılmaz MA; Şanlı HE; Kalay Yıldızhan İ; Mülayim MK; Çiçek D; Demir B; Yasak Güner R; Baykal Selçuk L; Gündüz K; Daye M; Borlu M; Solak EO; Dizman D; Güneş B; Ozkur E; Polat M; Eskiocak AH; Uzun S
Australas J Dermatol; 2021 Nov; 62(4):e496-e503. PubMed ID: 34642934
[TBL] [Abstract][Full Text] [Related]
43. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.
Langan SM; Smeeth L; Hubbard R; Fleming KM; Smith CJ; West J
BMJ; 2008 Jul; 337(7662):a180. PubMed ID: 18614511
[TBL] [Abstract][Full Text] [Related]
44. Bullous pemphigoid and antecedent neurological diseases: An association with dementia.
Yu Phuan CZ; Yew YW; Tey HL
Indian J Dermatol Venereol Leprol; 2017; 83(4):457-461. PubMed ID: 28584223
[TBL] [Abstract][Full Text] [Related]
45. Spectrum of autoimmune bullous diseases in Kuwait.
Nanda A; Dvorak R; Al-Saeed K; Al-Sabah H; Alsaleh QA
Int J Dermatol; 2004 Dec; 43(12):876-81. PubMed ID: 15569006
[TBL] [Abstract][Full Text] [Related]
46. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature.
Sami N; Ahmed AR
Dermatology; 2001; 202(4):293-301. PubMed ID: 11455140
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical study of toll-like receptors 2, 4, and 9 expressions in pemphigus and bullous pemphigoid lesions.
Sun XK; Chen JF; Shen H
Arch Dermatol Res; 2016 Aug; 308(6):429-36. PubMed ID: 27221282
[TBL] [Abstract][Full Text] [Related]
48. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.
Bertram F; Bröcker EB; Zillikens D; Schmidt E
J Dtsch Dermatol Ges; 2009 May; 7(5):434-40. PubMed ID: 19170813
[TBL] [Abstract][Full Text] [Related]
49. Frequency of IgA antibodies in pemphigus, bullous pemphigoid and mucous membrane pemphigoid.
Cozzani E; Drosera M; Parodi A; Carrozzo M; Gandolfo S; Rebora A
Acta Derm Venereol; 2004; 84(5):381-4. PubMed ID: 15370705
[TBL] [Abstract][Full Text] [Related]
50. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan.
Ogawa H; Sakuma M; Morioka S; Kitamura K; Sasai Y; Imamura S; Inaba Y
J Dermatol Sci; 1995 Mar; 9(2):136-41. PubMed ID: 7772576
[TBL] [Abstract][Full Text] [Related]
51. Risk of bullous pemphigoid and pemphigus in patients on chronic dialysis: A nationwide population-based cohort study.
Tang CH; Sue YM; Chang CL; Wang CC
J Dermatol; 2023 Dec; 50(12):1568-1575. PubMed ID: 37665203
[TBL] [Abstract][Full Text] [Related]
52. Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.
Kim M; Borradori L; Murrell DF
Drugs Aging; 2016 Oct; 33(10):711-723. PubMed ID: 27738963
[TBL] [Abstract][Full Text] [Related]
53. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
54. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases.
Stanley JR
J Clin Invest; 1989 May; 83(5):1443-8. PubMed ID: 2651476
[No Abstract] [Full Text] [Related]
55. Pemphigus and bullous pemphigoid in the United States: a 21-year analysis of patient characteristics, treatment patterns, and comorbidities.
Gutierrez Y; Pourali SP; Singh I; Armstrong AW
J Dermatolog Treat; 2022 Jun; 33(4):2383-2385. PubMed ID: 33769922
[No Abstract] [Full Text] [Related]
56. Biological therapy of autoimmune blistering diseases.
Alaibac M
Expert Opin Biol Ther; 2019 Feb; 19(2):149-156. PubMed ID: 30558452
[TBL] [Abstract][Full Text] [Related]
57. Coexistence of pemphigus foliaceus and bullous pemphigoid. Demonstration of autoantibodies that bind to both the pemphigus foliaceus antigen complex and the bullous pemphigoid antigen.
Korman NJ; Stanley JR; Woodley DT
Arch Dermatol; 1991 Mar; 127(3):387-90. PubMed ID: 1998370
[TBL] [Abstract][Full Text] [Related]
58. The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study.
Kridin K; Schonmann Y; Weinstein O; Schmidt E; Ludwig RJ; Cohen AD
J Am Acad Dermatol; 2021 Jul; 85(1):79-87. PubMed ID: 33744354
[TBL] [Abstract][Full Text] [Related]
59. Granulocyte activation in bullous diseases: release of granular proteins in bullous pemphigoid and pemphigus vulgaris.
Czech W; Schaller J; Schöpf E; Kapp A
J Am Acad Dermatol; 1993 Aug; 29(2 Pt 1):210-5. PubMed ID: 8393016
[TBL] [Abstract][Full Text] [Related]
60. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid.
Hofmann SC; Kautz O; Hertl M; Sticherling M; Zillikens D; Bruckner-Tuderman L
J Dtsch Dermatol Ges; 2009 Mar; 7(3):227-33. PubMed ID: 19371245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
